share_log

In8bio | DEF 14A: Definitive information statements

In8bio | DEF 14A: Definitive information statements

In8bio | DEF 14A：股东委托书决议
美股sec公告 ·  04/26 16:05
Moomoo AI 已提取核心信息
IN8bio, Inc., a biotechnology company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 12, 2024, at 9:00 a.m. Eastern Time. Stockholders of record as of April 17, 2024, are invited to attend and vote at the meeting, which will be accessible via live webcast. The proxy statement outlines the matters to be voted on, including the election of two Class III directors to serve until the 2027 Annual Meeting and the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company emphasizes the importance of stockholder votes, urging them to vote by proxy to ensure their representation, regardless of their attendance plans. Additional details regarding the meeting and the business to be conducted are described in the accompanying proxy statement.
IN8bio, Inc., a biotechnology company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 12, 2024, at 9:00 a.m. Eastern Time. Stockholders of record as of April 17, 2024, are invited to attend and vote at the meeting, which will be accessible via live webcast. The proxy statement outlines the matters to be voted on, including the election of two Class III directors to serve until the 2027 Annual Meeting and the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The company emphasizes the importance of stockholder votes, urging them to vote by proxy to ensure their representation, regardless of their attendance plans. Additional details regarding the meeting and the business to be conducted are described in the accompanying proxy statement.
生物技术公司In8Bio, Inc. 宣布已向美国证券交易委员会（SEC）提交其即将举行的2024年年度股东大会的最终委托书（DEF 14A）。该会议定于美国东部时间2024年6月12日上午9点以虚拟方式举行。截至2024年4月17日的登记股东将被邀请出席会议并在会上投票，会议将通过网络直播观看。委托书概述了有待表决的事项，包括选举两名三类董事任期至2027年年会，以及批准CohnrezNick LLP作为截至2024年12月31日的财政年度的独立注册会计师事务所。该公司强调股东投票的重要性，敦促他们通过代理人投票，以确保他们的代表性，无论他们的出勤计划如何。随附的委托书中描述了有关会议和将要开展的业务的其他细节。
生物技术公司In8Bio, Inc. 宣布已向美国证券交易委员会（SEC）提交其即将举行的2024年年度股东大会的最终委托书（DEF 14A）。该会议定于美国东部时间2024年6月12日上午9点以虚拟方式举行。截至2024年4月17日的登记股东将被邀请出席会议并在会上投票，会议将通过网络直播观看。委托书概述了有待表决的事项，包括选举两名三类董事任期至2027年年会，以及批准CohnrezNick LLP作为截至2024年12月31日的财政年度的独立注册会计师事务所。该公司强调股东投票的重要性，敦促他们通过代理人投票，以确保他们的代表性，无论他们的出勤计划如何。随附的委托书中描述了有关会议和将要开展的业务的其他细节。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息